Immune Suppression Of Infants Treated With Steroids
|ClinicalTrials.gov Identifier: NCT00433940|
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : January 24, 2013
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||16 participants|
|Official Title:||Immune Suppression of Infants Treated With Oral Corticosteroids for Infantile Hemangiomas: A Pilot Study|
|Study Start Date :||October 2006|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||July 2010|
Infantile Hemangioma Patients
Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
Other Name: steroid
- Lymphocyte Subtest of Complete Blood Count Analysis (Primary Immunodeficiency) [ Time Frame: 2 years ]Measurement of absolute lymphocyte count and % lymphocyte found during a Complete Blood Count analysis.
Biospecimen Retention: None Retained
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433940
|United States, Wisconsin|
|Children's Hospital of Wisconsin|
|Milwaukee, Wisconsin, United States, 53226|
|Principal Investigator:||Beth A Drolet, MD||Medical College of Wisconsin|